posed to contribute to the exceptionally high rate of included the targeted concentrations of serum phosphorus, calcium, and intact parathyroid hormone (PTH), and calcification cardiovascular disease in ESRD, including the adverse of the coronary arteries and thoracic aorta using a calcification hemodynamic effects of dialysis, oxidative stress, inflamscore derived from electron beam tomography.
mation, hypertension, hyperhomocysteinemia, and the
Results. Sevelamer and calcium provided equivalent control relatively infrequent use of aspirin, lipid-lowering agents, of serum phosphorus (end-of-study values 5.1 Ϯ 1.2 and 5.1 Ϯ 1.4 mg/dL, respectively, P ϭ 0.33). Serum calcium concentraand beta-adrenergic antagonists [3] [4] [5] [6] [7] . Disorders of mintion was significantly higher in the calcium-treated group (P ϭ eral metabolism (principally hyperphosphatemia, hyper-0.002), and hypercalcemia was more common (16% vs. 5% calcemia, and hyperparathyroidism) have also been prowith sevelamer, P ϭ 0.04). More subjects in the calcium group had end-of-study intact PTH below the target of 150 to 300 posed to play a role [8] . Epidemiological studies have pg/mL (57% vs. 30%, P ϭ 0.001). At study completion, the shown a direct correlation between serum phosphorus and median absolute calcium score in the coronary arteries and the calcium-phosphorus product and mortality in hemoaorta increased significantly in the calcium treated subjects but dialysis patients [9, 10] . Recently, Goodman et al showed not in the sevelamer-treated subjects (coronary arteries 36.6 vs. 0, P ϭ 0.03 and aorta 75.1 vs. 0, P ϭ 0.01, respectively). a striking degree of coronary artery calcification in young
The median percent change in coronary artery (25% vs. 6%, adults with ESRD, using electron beam tomography P ϭ 0.02) and aortic (28% vs. 5%, P ϭ 0.02) calcium score (EBT) [11] . In that study, the calcium-phosphorus product also was significantly greater with calcium than with sevelamer.
Conclusions. Compared with calcium-based phosphate bindand the dose of oral calcium ingested were significantly ers, sevelamer is less likely to cause hypercalcemia, low levels associated with the likelihood of coronary calcification.
of PTH, and progressive coronary and aortic calcification in
Based on these findings, we hypothesized that sevehemodialysis patients.
lamer, a non-absorbed, non-calcium-containing polymer, would be less likely to lead to progressive cardiovascular 1 The Treat to Goal Working Group members include (United States) calcification than calcium-based phosphate binders.
were excluded from participation: serious gastrointestinal disease (including dysphagia, active untreated gas- fasting samples [13, 14] . All blood samples were analyzed at Quest Diagnostics (Van Nuys, CA, USA and Heston, Washout (run-in) phase. After screening, subjects underwent a two-week washout period in which all phosMiddlesex, UK). These laboratories used the same standardized assays. phate binders were withheld (weeks Ϫ2 to 0). Subjects who developed hyperphosphatemia (serum phosphorous Imaging procedures. Subjects underwent an EBT imaging procedure at days 0 and at 26 and 52 weeks. EBT Ͼ5.5 mg/dL) during the washout period were eligible for randomization.
imaging procedures were performed on C-150 scanners (GE-Imatron, South San Francisco, CA, USA) with a Randomization. Patients were randomized in a 1:1 ratio to receive either sevelamer or calcium, stratified 100-msec scanning time and a single-slice thickness of three millimeters. Thirty-six to 40 tomographic slices by site and the presence of diabetes at screening. The randomization schedule was computer generated using were obtained for each subject during a single breathholding period. Tomographic imaging was electrocardio-SAS 6.12 (Cary, NC, USA).
Treatment phase. Subjects were randomized to sevegraphically triggered at 60 or 80% of the R-R interval (according to each individual imaging center's protocol) lamer (Renagel 800 mg tablets; GelTex Pharmaceuticals, Waltham, MA, USA) or calcium-based binders.
and proceeded from the level of the carina to the diaphragm. Thus, this imaging protocol prevented the visuSubjects treated with calcium in the US received calcium acetate (PhosLo 667 mg tablets; Braintree Pharmaceualization of a portion of the aortic arch. All areas of calcification with a minimal density of 130 Hounsefield ticals, Inc., Braintree, MA, USA) and subjects in Europe were treated with calcium carbonate (Sertuerner 500 units (HU) within the borders of the coronary arteries, aorta, mitral valve, and aortic valve were computed. A mg tablets; Sertuerner Arzneimittel GmbH, Guetersloh, Germany). Due to the size, appearance, and taste of the calcified plaque was considered present if at least three contiguous pixels with a density of Ն130 HU were detablets, neither the subjects nor the investigators were blinded to the treatment regimen. Adherence to treattected (an area equivalent to 1.03 mm 2 ). The acquired images were reviewed on a NetraMD ment was estimated by pill counts.
The treatment phase lasted 52 weeks. During the first workstation (ScImage, Los Altos, CA, USA). The total volume and density of calcification were derived for the 12 weeks, the dose of phosphate binder was titrated every three weeks to achieve serum phosphorous and coronary arteries and aorta, mitral valve, and aortic valve. The traditional calcium score originally described calcium concentrations in the target ranges of 3.0 to 5.0 mg/dL and 8.5 to 10.5 mg/dL, respectively. Serum by Agatston et al [15] and an interpolated volume score viewer analyzed a random sample of 10% of all the scans. The inter-rater agreement was 100% for the presence or absence of calcification, and Ͼ90% of total scores were within 15% of each other for the two reviewers. groups were compared with the Wilcoxon signed rank test. Between groups comparisons were performed using For descriptive purposes, subjects were classified into four coronary calcification groups: none (calcium score ϭ the Fisher exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. 0), mild to moderate (calcium score ϭ 1 to 400), severe (calcium score ϭ 401 to 1000), and very severe (calcium Evaluation of the change in calcification was performed in several ways owing to imperfections of each score Ͼ1000). This classification is a modification of the categorization proposed by Rumberger et al [19] . Calapproach. The first method was calculation of the absolute change in calcification score (26-or 52-week value cium scores Ͼ400 indicate severe and extensive atherosclerotic disease. Non-uremic patients with calcification minus baseline value). While simple, this approach weighs more heavily those subjects with extensive baseline calciscores in this range are very likely to have obstructive coronary artery disease (CAD), with a high risk of develfication who are more likely to experience larger nominal changes in calcification (in either direction) [18] . The oping symptomatic myocardial ischemia [19] . For this study, the classification was modified to accommodate relative (percent) change in calcification score was also calculated. While easy to interpret, this approach runs the more extensive degree of calcification observed in the hemodialysis population. Therefore, the mild and the risk of weighing more heavily those subjects with less extensive baseline calcification [18] . For example, a moderate categories were combined into a single category. Additionally, a fourth group, "very severe," was subject who experienced an increase in calcification score from 10 to 20 (100%) would be considered to have inintroduced to categorize those subjects with markedly elevated calcium scores. There is no published classificacreased his or her calcification burden more than a subject whose score increased from 500 to 900 (80%). To tion scheme for aortic calcification scores. Therefore, we divided subjects into a group without aortic calcification avoid extreme percent increases among individuals with little or no baseline calcification, we excluded subjects and further divided the remaining subjects with calcification into tertiles.
with baseline calcification scores below 30 in the relative change analyses as done in a prior study [20] . We reStatistical analysis solved to report absolute and relative effects of the study treatments on calcification, recognizing that qualitatively Pretreatment characteristics were compared between the sevelamer and calcium groups using the Fisher exact and quantitatively consistent results in both analyses would be required for our conclusions to be robust. To test for categorical variables and the Wilcoxon rank sum test for continuous variables. All laboratory analyses determine the effect of baseline calcification on subsequent calcification, we used mixed model regression on were performed using a last value carried forward approach. Changes from baseline to end-of-study within ranked changes of coronary artery and aortic calcifica- Randomization began on May 26, 1999 and ended on January 19, 2000. The last subject completed the study on January 25, 2001. Baseline characteristics of study subjects are summarized in Table 1 . Adherence to the ate in Europe was 3.9 g (equivalent to ϳ8 Sertuerner prescribed dose was 86% in the sevelamer group and 500 mg tablets). 80% in the calcium group (P ϭ 0.03). Sevelamer subjects Biochemical end points ingested an average of 6.5 Ϯ 2.9 g of binder per day (equivalent to ϳ8 Renagel 800 mg tablets) compared Table 2 summarizes the key biochemical end points. with calcium subjects who ingested an average dose of Baseline values represent laboratory test results ob-4.3 Ϯ 1.9 g per day. The average dose of calcium acetate tained after a two-week phosphate binder-free washout in the United States was 4.6 g (equivalent to ϳ7 PhosLo period. Over the course of the study, 17% of sevelamer subjects and 43% of calcium subjects experienced at least 667 mg tablets) and the average dose of calcium carbon-one hypercalcemic episode (P ϭ 0.0005). Suppression of intact PTH below the 150 to 300 pg/mL target range was more common at the end of the study in the calcium group (57 vs. 30%, P ϭ 0.001) despite the protocolspecified reduction or cessation of vitamin D for intact PTH below 150 pg/mL. Indeed, over the maintenance phase of treatment, vitamin D usage (expressed as an equivalent dose of 1,25-dihydroxy vitamin D 3 ) decreased by approximately 0.25 g/week in the calcium-treated subjects and increased by approximately 0.25 g/week in the sevelamer-treated subjects. Twelve percent of subjects in the calcium group required rescue aluminum for a calcium-phosphorus product Ͼ72 mg 2 /dL 2 compared with 4% of subjects on sevelamer (P ϭ 0.07). LDL cholesterol declined substantially for the sevelamer group (mean 37 Ϯ 20%, P Ͻ 0.0001) but not the calcium treated group as expected per prior experience [21] .
The effects of calcium and sevelamer on biochemical end points were consistent across study sites (US vs. Europe) and were not significantly influenced by age, gender, race, diabetes, or baseline vitamin D prescription (data not shown).
Cardiovascular calcification
At baseline, EBT detected coronary artery calcification in 83% and aortic calcification in 80% of study subjects. Mitral valve calcification was observed in 46% and aortic valve calcification in 35% of study subjects. Table 3 summarizes the baseline EBT scores for coronary arteries and aorta. Of the 200 randomized patients 14 did not undergo EBT imaging. Therefore, the data in Table 3 scores from baseline to week 26 and week 52 in patients with calcification (scores Ն30) at baseline. *Indicates within-treatment, P Ͻ 0.001. Comare based on an initial imaging cohort of 186 patients.
parisons between calcium-treated ( ) and sevelamer-treated () groups, P ϭ 0.01 at week 26 and P ϭ 0.02 at week 52. Corresponding
Absolute changes in calcification score
values for volume score were 9% versus 18% (P ϭ 0.02) for sevelamer and calcium at week 26, respectively, and 10% versus 28% (P ϭ 0.04) for Absolute changes in calcification scores in the two sevelamer and calcium at week 52, respectively. (B) Median percentage treatment groups are summarized in Table 4 . change in aortic calcification scores from baseline to week 26 and week There was significant progression of coronary artery 52 in patients with calcification (scores Ն30) at baseline. *Indicates within treatment, P Ͻ 0.001. Comparisons between calcium-and seveand aortic calcification in the calcium group at both time lamer-treated groups, P ϭ 0.01 at week 26 and P ϭ 0.02 at week 52.
points (mean and median scores positive), and no sigCorresponding values for volume score were 10% versus 23% (P ϭ nificant progression in the sevelamer group (mean scores 0.02) for sevelamer and calcium at week 26, respectively, and 22% versus 37% (P ϭ 0.05) for sevelamer and calcium at week 52, respectively. negative, median scores zero). All comparisons between groups were statistically significant. Mitral valve and aortic valve scores did not change significantly in either group (data not shown).
while the relative score changes for sevelamer treated subjects were not. For the sevelamer treated subjects the Relative change in calcification score median (interquartile range) percent changes at 52 weeks Of the 25 subjects with no coronary calcification at for the coronary arteries and aorta were 6% (Ϫ14 to baseline, 20 continued to have no calcification on repeat 24%) and 5% (Ϫ21 to 39%), respectively. For the calscans. Similarly, of the 32 subjects with no aortic calcificium treated patients the median (interquartile range) cation at baseline, 27 continued to have no calcification percent changes at 52 weeks were 25% (Ϫ5 to 63%) and on repeat scans. These subjects were excluded from anal-28% (3 to 79%) for the coronary arteries and aorta, yses of relative change (Methods section). Figure 1 shows respectively. the relative increase in coronary artery and aortic calcifi-
The between treatment comparisons were statistically cation at 26 and 52 weeks. The relative changes measured in calcium treated subjects were statistically significant significant (see Fig. 1 legend) . Figure 2 shows an example of comparative EBT scans in a patient treated with seve-DISCUSSION lamer.
In this study, 200 hemodialysis subjects were randomized to receive either sevelamer or calcium salts for treatEffect of baseline calcification and other factors ment of hyperphosphatemia. The control of serum phosThe degree of baseline calcification was directly correphorus was equivalent with both agents, although subjects lated with the likelihood and degree of absolute progresrandomized to calcium experienced significantly more sion over time. The between group differences in calcifihypercalcemia and intact PTH levels below the targeted cation were amplified in subjects with more severe range. Furthermore, both coronary artery and aortic calbaseline calcification of coronary arteries and aorta (P ϭ cification progressed significantly with calcium but not 0.03 and P ϭ 0.04 for the interaction, respectively). This with sevelamer. The difference was detectable as early as was observed with both the Agatston score and the volsix months and continued to be significant at one year. ume score (P ϭ 0.01 and P ϭ 0.27). Figure 3 illustrates Calcium was initially thought to be especially effective the progression of coronary artery and aortic volume in patients with ESRD, not only because of its efficacy scores by baseline severity groupings.
as a phosphate binder, but also because of its direct effect (via normalizing or raising above normal the level of Safety serum calcium) on secondary hyperparathyroidism and In general all binders were well tolerated. Routine associated high turnover bone disease. However, recent biochemical safety parameters were similar between the evidence suggests that the use of high-dose calcium salts treatment groups except for serum bicarbonate, which in ESRD might not be as benign as previously suspected was higher in the calcium treated subjects (22.1 Ϯ 4.4 [11] . Sevelamer is a nonabsorbed polymer (calcium and mEq/L vs. 19.2 Ϯ 4.3 mEq/L, P ϭ 0.0003) as the calcium metal free) that has proved to be an effective phosphate salts provide base and sevelamer does not. There were binder [21, 22] . It also acts as a bile acid sequestrant and six deaths in the sevelamer group and five deaths in the is therefore capable of reducing LDL cholesterol levels calcium group. A total of 37 subjects on sevelamer were [21] . In an open label study sevelamer taken alone led hospitalized compared with 48 subjects on calcium (P ϭ to a gradual increase in intact PTH. Thus, a combination 0.15). Sevelamer-treated subjects were hospitalized for of sevelamer and vitamin D metabolites may be required at total of 567 days compared with 980 days for the to optimize control of hyperparathyroidism [23] . Vascular calcification is strongly associated with an incalcium-treated subjects (P ϭ 0.23).
which the progression of calcification over time has been influenced by any means.
A possible mechanism explaining the observed treatment effects may be ongoing calcium loading related to oral calcium ingestion. This would be consistent with the findings of Goodman et al and Gué rin et al, who reported an association of the dose of oral calcium and the risk of vascular calcification [11, 36] . Notably, the serum calcium may not reflect the total body calcium load, and excess calcium may be particularly prone to deposit in the tissues when the serum phosphorus is high and when the intact PTH is low, the latter reflecting a state of low bone turnover [12] . Other factors unrelated to calcium, such as the favorable effect of sevelamer on LDL cholesterol, also may have contributed to the study's findings. In a cross sectional analysis of these study subjects, we found serum phosphorous, calcium, and intact PTH to be related to coronary and aortic calcification, while total, LDL, and HDL cholesterol were not [8] . Callister et al demonstrated that HMG Co-A reductase inhibitors reduce or arrest the progression of coronary artery calcification in persons with normal renal function [20] . Whether statins would reduce coronary and aortic calcification in persons with ESRD is unknown.
Limitations of the study include the relatively brief period of observation (1 year), the absence of subjects on peritoneal dialysis, and the inability of EBT to distinguish between intimal (atherosclerotic) and medial calcification, although both carry a negative prognosis for cardiovascular events. While both treatments were able to achieve excellent control of serum phosphorus and calcium-phosphorus product, the study failed to achieve the end point for which it was powered (a 10 mg 2 /dL 2 difference in end-of-study calcium-phosphorus product between study groups). Nevertheless, the calcium-phosNominal change in aorta volume scores from baseline to week 52 by phorus product was marginally lower in the sevelamer baseline calcification group. Symbols are: () sevelamer; ( ) calcium. group and the serum calcium and intact PTH levels were more likely within target ranges. Finally, we cannot determine the exact mechanism of the relative protection afforded by sevelamer. Additional studies will be required creased risk of cardiovascular events and mortality in both to determine whether reduced calcium intake, fewer epinon-uremic and uremic patients [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Like in the nonsodes of hypercalcemia, improved control of intact PTH, uremic patient, calcification in ESRD occurs in the arteor other metabolic effects (such as, lipids) are responsible rial intima in association with atherosclerotic plaques [35] .
for the benefit. At present, it is difficult to ascribe the proHowever, medial calcification can also occur and probably gression in calcification to vitamin D per se, since usage increases arterial stiffness and ventricular afterload [36] .
was increased in the sevelamer-treated subjects who exIncreased arterial stiffness in turn has been associated perienced less calcification over time. with increased cardiovascular mortality in ESRD [33, 34] .
In summary, herein we provide evidence that treatIn observational studies, cardiovascular calcification ment with sevelamer results in fewer episodes of hyperin ESRD has been variably associated with age, dialysis calcemia, improved control of PTH and attenuation of vintage, race, diabetes, serum phosphorus, calcium, HDL the progression of coronary artery and aortic calcificacholesterol and triglyceride concentrations, markers of tion relative to calcium salts. It remains to be demoninflammation, and higher doses of calcium salts used as strated whether attenuation of coronary artery and aortic phosphate binders [8, 11, [36] [37] [38] . However, to our knowlcalcification will translate into a reduction in the burden of cardiovascular disease in this vulnerable population. edge this is the first study in patients with ESRD in
